NCT07470840 2026-03-17
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
Clinical Trials
14 trialsNCT06388720 2025-09-15
IMGeS
National Cancer Center, Korea
Phase 2 Recruiting
NCT06670300 2024-11-01
Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT03058757 2023-01-31
The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation
National Cancer Center, Korea
Phase 2 Completed
NCT03062059 2022-04-14
The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence
National Cancer Center, Korea
Phase 2 Unknown
NCT02860819 2021-03-03
Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer
National Cancer Institute, Slovakia
Phase 2 Completed
NCT04383067 2021-02-11
A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients
Sheba Medical Center
Phase 2 Unknown
NCT04184232 2021-01-22
Treatment of Recurrent Bladder Cancer With Dendritic Cells
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Phase 2 Completed
NCT04523896 2020-08-24
BRAchySABR
Biobizkaia Health Research Institute
Phase 2 Unknown
NCT03403777 2019-03-05
Avelumab in Refractory Testicular Germ Cell Cancer.
National Cancer Institute, Slovakia
Phase 2 Completed
NCT02626754 2018-06-26
A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
Taipei Veterans General Hospital, Taiwan
Phase 2 Terminated
NCT02002455 2016-10-21
Flucipro
Turku University Hospital
Phase 2 Completed
NCT01791387 2015-02-03
DILIGENCE-1
Auckland District Health Board
Phase 2 Unknown
NCT00657982 2009-01-21
Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer
Sheba Medical Center
Phase 2 Unknown